Abstract
Neither losartan- nor atenolol-based antihypertensive regimens could prevent the progression of aortic valve (AV) sclerosis in elderly, high-risk hypertensive patients, and the regression of AV sclerosis did not translate into reduced cardiovascular risk.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Aortic Valve / pathology*
-
Aortic Valve / physiopathology
-
Atenolol / therapeutic use*
-
Female
-
Heart Valve Diseases / drug therapy*
-
Heart Valve Diseases / pathology*
-
Heart Valve Diseases / physiopathology
-
Humans
-
Losartan / therapeutic use*
-
Male
-
Middle Aged
-
Sclerosis